Fluoxétine (DrugBank: Fluoxétine)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 17 | 多系統萎縮症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01136213 (ClinicalTrials.gov) | April 2010 | 26/5/2010 | Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study | Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study | Multiple System Atrophy | Radiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / Placebo | University Hospital, Bordeaux | NULL | Completed | 30 Years | 80 Years | All | 53 | N/A | France |
| 2 | EUCTR2007-004922-26-FR (EUCTR) | 12/02/2008 | 31/01/2008 | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | atrophie multisystématisée MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: PROZAC | CHU Toulouse | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France |